Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257485 | 0.85 | AKR1B1 (0.39) | MEN1KMT2ACYP3A4TDP1CYP2C19 | |
| SCHEMBL12117477 | 0.85 | CYP3A4 (0.54) | TRPM8TP53MEN1KMT2ACYP3A4 | |
| SCHEMBL30443001 | 0.85 | CYP3A4 (0.54) | TRPM8TP53MEN1KMT2ACYP3A4 | |
| SCHEMBL29943820 | 0.84 | BCL2A1 (0.39) | TP53MEN1KMT2ATDP1POLB | |
| SCHEMBL4832843 | 0.84 | BCL2A1 (0.39) | TP53MEN1KMT2ATDP1POLB | |
| SCHEMBL2921603 | 0.84 | NPSR1 (0.39) | MEN1KMT2ACYP3A4TDP1NPSR1 | |
| SCHEMBL4832911 | 0.84 | LMNA (0.41) | LMNAALDH1A1TDP1POLBCYP2C19 | |
| SCHEMBL4842133 | 0.83 | SMN1; SMN2 (0.38) | TDP1NPSR1CYP2C19HIF1AL3MBTL1 | |
| SCHEMBL4841484 | 0.83 | KMT2A (0.43) | TP53MEN1KMT2ALMNATDP1 | |
| SCHEMBL4031047 | 0.82 | TRPM8 (0.44) | TRPM8TP53MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-20120101143-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-04-26 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7939558-B2 | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20080319008-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| EP-1765347-A4 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | UNIV CALIFORNIA (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6649606-B1 | Treating inflammatory diseases | BRISTOL-MYERS SQUIBB CO. | 2003-11-18 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003041641-A2 | TETRAHYDROISOQUINOLINE ANALOGS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | TRPM8 4563/4885TP53 408/4885MEN1 1818/4885 |
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | TRPM8 3969/4885TP53 2550/4885MEN1 3582/4885 |
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | TRPM8 3675/4885TP53 4519/4885MEN1 1712/4885 |
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | TRPM8 4027/4885TP53 4284/4885MEN1 3220/4885 |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | TRPM8 4563/4885TP53 408/4885MEN1 1818/4885 |
| US-20080319008-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | CFTR, ABCC9, SLC26A4 | TRPM8 232/4885TP53 2168/4885MEN1 4502/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | TRPM8 4280/4885TP53 4473/4885MEN1 1959/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | TRPM8 4280/4885TP53 4473/4885MEN1 1959/4885 |
| US-20120101143-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof | CFTR, ABCC9, ABCB11 | TRPM8 237/4885TP53 2185/4885MEN1 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.